Moderna led S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S. The biotech company is developing a vaccine for H5N1.

CDC officials ... for an mRNA-based vaccine to enable the licensure of a pre-pandemic vaccine against H5 influenza virus,” the company said at the time. Moderna’s stock was down 2.7% Thursday ...

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi ... [+] Images/GHI/UCG/Universal Images Group via Getty Images) The stock price of Moderna saw a 12% jump on ...

Moderna stock (MRNA) fell over 9% on Wednesday, forfeiting most of its gains from Tuesday's session during a volatile week for the stock seen after the first reported bird flu death in the US ...

Moderna (MRNA) stock is spiraling Wednesday ... Moderna's mRNA pipeline tracker currently shows that vaccine is in Phase 3 studies. As of January 6, the CDC noted that there have been 66 confirmed ...

Vaccine stocks are volatile after the first US bird flu death and a CDC report on rising respiratory ... which allows you to own portions of stock without buying an entire share.